Related Experiment Video
Updated: Dec 3, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Chinese expert consensus on Anlotinib Hydrochloride for advanced lung cancer (2020 edition)]
Abstract:
Anlotinib hydrochloride is the only anti-angiogenic, multi-targeted tyrosine kinase inhibitor, which has been approved for non-small cell lung cancer and small cell lung cancer in China. In order to provide guidance for clinical practitioners to use anlotinib hydrochloride safely and efficiently, the Chinese Association for Clinical Oncologists, the Expert Committee of Vascular Targeted Therapy of Chinese Society of Clincal Oncology and the Cancer Targeted Therapy Professional Committee of China Anti-Cancer Association co-organized experts and integrated multiple evidences of Anlotinib Hydrochloride, from both clinical trial, post-marketed clinical data and the associated experiences of experts accumulated in clinical practice, etc. The present consensus covers the clinical data of anlotinib hydrochloride applied in advanced non-small cell lung cancer and small cell lung cancer, and the safety management recommendations.
Insights
Anlotinib hydrochloride, a multi-targeted tyrosine kinase inhibitor, offers guidance for safe and effective use in advanced lung cancers. This consensus integrates clinical data and expert experience for non-small cell and small cell lung cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Anlotinib hydrochloride is an approved anti-angiogenic, multi-targeted tyrosine kinase inhibitor in China.
- It is indicated for advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
- Clinical guidance is needed for safe and efficient use of anlotinib hydrochloride.
Purpose of the Study:
- To provide clinical practitioners with evidence-based guidance for anlotinib hydrochloride.
- To consolidate clinical trial data, post-marketed data, and expert experience.
- To establish safety management recommendations for anlotinib hydrochloride in lung cancer treatment.
Main Methods:
- Integration of multiple evidence sources.
- Review of clinical trial data for anlotinib hydrochloride.
- Analysis of post-marketed clinical data and expert clinical practice experiences.
Main Results:
- The consensus covers clinical data of anlotinib hydrochloride in advanced NSCLC and SCLC.
- It includes safety management recommendations for anlotinib hydrochloride.
- The integrated evidence supports optimal use of anlotinib hydrochloride.
Conclusions:
- Anlotinib hydrochloride is a valuable therapeutic option for advanced NSCLC and SCLC.
- This consensus provides essential guidance for safe and effective clinical application.
- Adherence to safety recommendations is crucial for maximizing patient benefit from anlotinib hydrochloride.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...